Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report
- 31 August 2001
- journal article
- clinical trial
- Published by Elsevier in Seminars in Oncology
- Vol. 28, 40-44
- https://doi.org/10.1016/s0093-7754(01)90153-8
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate CancerJournal of Clinical Oncology, 2001
- Neoadjuvant Chemotherapy and Hormonal Therapy Followed by Radical Prostatectomy: Feasibility and Preliminary ResultsJournal of Clinical Oncology, 2000
- Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?Journal of Clinical Oncology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinomaAnnals of Oncology, 1999
- MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTSJournal of Urology, 1998
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989